Oxford BioMedica plc’s (OXB) “Buy” Rating Reiterated at Peel Hunt

Peel Hunt reaffirmed their buy rating on shares of Oxford BioMedica plc (LON:OXB) in a research note released on Tuesday morning, MarketBeat Ratings reports. Peel Hunt currently has a GBX 13 ($0.17) target price on the biopharmaceutical company’s stock.

OXB has been the topic of several other reports. N+1 Singer raised their price target on shares of Oxford BioMedica plc from GBX 7.80 ($0.10) to GBX 8.70 ($0.11) and gave the stock a hold rating in a research note on Thursday, July 27th. Jefferies Group LLC reaffirmed a buy rating and set a GBX 13 ($0.17) target price on shares of Oxford BioMedica plc in a research note on Thursday, August 31st. Finally, Shore Capital reaffirmed a not rated rating on shares of Oxford BioMedica plc in a research note on Thursday, July 13th.

Oxford BioMedica plc (OXB) opened at GBX 8.91 ($0.12) on Tuesday.

TRADEMARK VIOLATION NOTICE: This news story was posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.com-unik.info/2017/11/04/oxford-biomedica-plcs-oxb-buy-rating-reiterated-at-peel-hunt.html.

In other news, insider Andrew Heath bought 110,511 shares of Oxford BioMedica plc stock in a transaction on Tuesday, September 26th. The shares were bought at an average cost of GBX 9 ($0.12) per share, with a total value of £9,945.99 ($13,124.82). Also, insider Martin Diggle bought 100,000 shares of Oxford BioMedica plc stock in a transaction on Friday, September 15th. The shares were purchased at an average cost of GBX 8 ($0.11) per share, for a total transaction of £8,000 ($10,556.88). Insiders have acquired 590,632 shares of company stock worth $5,215,688 over the last ninety days.

Oxford BioMedica plc Company Profile

Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company’s segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners.

What are top analysts saying about Oxford BioMedica plc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Oxford BioMedica plc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit